TG THERAPEUTICS INC (NASDAQ:TGTX) stands out as a compelling candidate for high-growth momentum investors, combining strong earnings momentum with a favorable technical breakout pattern. The biotech firm, focused on treatments for B-cell malignancies and autoimmune diseases, has demonstrated impressive growth metrics while presenting a well-defined technical setup.
Growth Momentum Highlights
Exceptional EPS Growth: TGTX reported a 142.9% year-over-year EPS increase in the most recent quarter, following a 250% jump in the prior quarter. Full-year EPS growth surged by 1,300%, reflecting strong profitability momentum.
Revenue Acceleration: Quarterly sales grew 90.4% YoY, with prior quarters showing even sharper increases (146% and 357% in preceding periods). Annual revenue climbed 40.8%, signaling sustained demand.
Positive Earnings Surprises: The company beat EPS estimates in two of the last four quarters by an average of 36.4%, while revenue surpassed expectations in all four quarters.
Profit Margin Expansion: Quarterly profit margins improved to 4.2% from negative territory in prior years, with full-year margins reaching 7.1%.
Technical Strength
TGTX scores a 9/10 on ChartMill’s Technical Rating, reflecting a strong uptrend with consistent performance across short and long-term timeframes. Key technical observations include:
Relative Strength: Outperforming 94% of all stocks and 91% of biotechnology peers.
Support Zones: Multiple support levels between $33.36 and $37.23 provide downside protection.
Consolidation Pattern: The stock has been trading in a tight range ($34.03 - $40.99) with reduced volatility, suggesting a potential breakout.
Setup Quality
With an 8/10 Setup Rating, TGTX presents a clear entry opportunity:
Breakout Level: A move above $37.76 could signal further upside.
Stop-Loss Zone: Support at $36.50 offers a logical exit point if the breakout fails.
Institutional Interest: Recent accumulation by large players adds confidence to the setup.
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors.